Global Immuno-Oncology Competitive Landscape Professional Research Report 2025

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $3,500	170 Pages	DIResearch	January, 2025	DIR19532046

Best Price Guarantee
Price	from $3,500
Length	170 Pages
Publisher	DIResearch
Published Date	January, 2025
SKU	DIR19532046

Global Immuno-Oncology Competitive Landscape Professional Research Report 2025

Research Summary

Immuno-oncology is a branch of cancer treatment that focuses on harnessing the body＇s immune system to recognize, target, and eliminate cancer cells. The field explores strategies to enhance the natural ability of the immune system to detect and destroy cancer cells, often by overcoming mechanisms that tumors use to evade immune detection. Immunotherapies in immuno-oncology include checkpoint inhibitors, adoptive cell transfer, cytokines, and cancer vaccines. Checkpoint inhibitors, such as PD-1 and CTLA-4 inhibitors, block proteins that inhibit immune responses, allowing T cells to recognize and attack cancer cells more effectively. Adoptive cell transfer involves manipulating a patient＇s own immune cells outside the body and then reintroducing them to target and destroy cancer cells. Immuno-oncology has shown promising results in treating various types of cancers and is a rapidly evolving field in the quest for more effective and targeted cancer therapies.

According to DIResearch's in-depth investigation and research, the global Immuno-Oncology market size was valued at XX Million USD in 2024 and is projected to reach XX Million USD by 2032, with a CAGR of XX% (2025-2032). Notably, the China market has changed rapidly in the past few years. By 2024, China's market size is expected to be XX Million USD, representing approximately XX% of the global market share. By 2032, it is anticipated to grow further to XX Million USD, contributing XX% to the worldwide market share.

The major global manufacturers of Immuno-Oncology include Bristol-Myers Squibb, Merck & Co., Inc., Roche AG, AstraZeneca, Plc, Sanofi S.A., Dendreon Pharmaceuticals, Novartis, Gilead Sciences Inc., Merck KGaA etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.

This report studies the market size, price trends and future development prospects of Immuno-Oncology. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major manufacturers, as well as the market status and trends of different product types and applications in the global Immuno-Oncology market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.

The regions and countries in the report include North America, Europe, China, APAC (excl. China), Latin America and Middle East and Africa, covering the Immuno-Oncology market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Immuno-Oncology industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.

The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.

Global Key Manufacturers of Immuno-Oncology Include:

Bristol-Myers Squibb

Merck & Co., Inc.

Roche AG

AstraZeneca, Plc

Sanofi S.A.

Dendreon Pharmaceuticals

Novartis

Gilead Sciences Inc.

Merck KGaA

Immuno-Oncology Product Segment Include:

Immune Checkpoint Inhibitors

Cytokine-Based Immunotherapy

Cancer Vaccines

CAR-T Cell Therapy

Others

Immuno-Oncology Product Application Include:

Hospitals

Drugstores

Others

Chapter Scope

Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trends

Chapter 2: Global Immuno-Oncology Industry PESTEL Analysis

Chapter 3: Global Immuno-Oncology Industry Porter’s Five Forces Analysis

Chapter 4: Global Immuno-Oncology Major Regional Market Size and Forecast Analysis

Chapter 5: Global Immuno-Oncology Market Size and Forecast by Type and Application Analysis

Chapter 6: North America Passenger Immuno-Oncology Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 7: Europe Immuno-Oncology Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 8: China Immuno-Oncology Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 9: APAC (Excl. China) Immuno-Oncology Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 10: Latin America Immuno-Oncology Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 11: Middle East and Africa Immuno-Oncology Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 12: Global Immuno-Oncology Competitive Analysis of Key Manufacturers (Revenue, Market Share, Regional Distribution and Industry Concentration)

Chapter 13: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)

Chapter 14: Industrial Chain Analysis, Include Raw Material Suppliers, Distributors and Customers

Chapter 15: Research Findings and Conclusion

Chapter 16: Methodology and Data Sources

1 Immuno-Oncology Market Overview: 1.1 Product Definition and Statistical Scope; 1.2 Immuno-Oncology Product by Type; 1.2.1 Immune Checkpoint Inhibitors; 1.2.2 Cytokine-Based Immunotherapy; 1.2.3 Cancer Vaccines; 1.2.4 CAR-T Cell Therapy; 1.2.5 Others; 1.3 Immuno-Oncology Product by Application; 1.3.1 Hospitals; 1.3.2 Drugstores; 1.3.3 Others; 1.4 Global Immuno-Oncology Market Size Analysis (2020-2032); 1.5 Immuno-Oncology Market Development Status and Trends; 1.5.1 Immuno-Oncology Industry Development Status Analysis; 1.5.2 Immuno-Oncology Industry Development Trends Analysis
2 Immuno-Oncology Market PESTEL Analysis: 2.1 Political Factors Analysis; 2.2 Economic Factors Analysis; 2.3 Social Factors Analysis; 2.4 Technological Factors Analysis; 2.5 Environmental Factors Analysis; 2.6 Legal Factors Analysis
3 Immuno-Oncology Market Porter's Five Forces Analysis: 3.1 Competitive Rivalry; 3.2 Threat of New Entrants; 3.3 Bargaining Power of Suppliers; 3.4 Bargaining Power of Buyers; 3.5 Threat of Substitutes
4 Global Immuno-Oncology Market Analysis by Regions: 4.1 Immuno-Oncology Overall Market: 2024 VS 2025 VS 2032; 4.2 Global Immuno-Oncology Revenue and Forecast Analysis (2020-2032); 4.2.1 Global Immuno-Oncology Revenue and Market Share by Region (2020-2025); 4.2.2 Global Immuno-Oncology Revenue Forecast by Region (2026-2032)
5 Global Immuno-Oncology Market Size by Type and Application: 5.1 Global Immuno-Oncology Market Size by Type (2020-2032); 5.2 Global Immuno-Oncology Market Size by Application (2020-2032)
6 North America: 6.1 North America Immuno-Oncology Market Size and Growth Rate Analysis (2020-2032); 6.2 North America Key Manufacturers Analysis; 6.3 North America Immuno-Oncology Market Size by Type; 6.4 North America Immuno-Oncology Market Size by Application; 6.5 North America Immuno-Oncology Market Size by Country; 6.5.1 US; 6.5.2 Canada
7 Europe: 7.1 Europe Immuno-Oncology Market Size and Growth Rate Analysis (2020-2032); 7.2 Europe Key Manufacturers Analysis; 7.3 Europe Immuno-Oncology Market Size by Type; 7.4 Europe Immuno-Oncology Market Size by Application; 7.5 Europe Immuno-Oncology Market Size by Country; 7.5.1 Germany; 7.5.2 France; 7.5.3 United Kingdom; 7.5.4 Italy; 7.5.5 Spain; 7.5.6 Benelux
8 China: 8.1 China Immuno-Oncology Market Size and Growth Rate Analysis (2020-2032); 8.2 China Key Manufacturers Analysis; 8.3 China Immuno-Oncology Market Size by Type; 8.4 China Immuno-Oncology Market Size by Application
9 APAC (excl. China): 9.1 APAC (excl. China) Immuno-Oncology Market Size and Growth Rate Analysis (2020-2032); 9.2 APAC (excl. China) Key Manufacturers Analysis; 9.3 APAC (excl. China) Immuno-Oncology Market Size by Type; 9.4 APAC (excl. China) Immuno-Oncology Market Size by Application; 9.5 APAC (excl. China) Immuno-Oncology Market Size by Country; 9.5.1 Japan; 9.5.2 South Korea; 9.5.3 India; 9.5.4 Australia; 9.5.5 Southeast Asia
10 Latin America: 10.1 Latin America Immuno-Oncology Market Size and Growth Rate Analysis (2020-2032); 10.2 Latin America Key Manufacturers Analysis; 10.3 Latin America Immuno-Oncology Market Size by Type; 10.4 Latin America Immuno-Oncology Market Size by Application; 10.5 Latin America Immuno-Oncology Market Size by Country; 10.5.1 Mexico; 10.5.2 Brazil
11 Middle East & Africa: 11.1 Middle East & Africa Immuno-Oncology Market Size and Growth Rate Analysis (2020-2032); 11.2 Middle East & Africa Key Manufacturers Analysis; 11.3 Middle East & Africa Immuno-Oncology Market Size by Type; 11.4 Middle East & Africa Immuno-Oncology Market Size by Application; 11.5 Middle East & Africa Immuno-Oncology Market Size by Country; 11.5.1 Saudi Arabia; 11.5.2 South Africa
12 Competition by Manufacturers: 12.1 Global Immuno-Oncology Market Revenue by Key Manufacturers (2021-2025); 12.2 Immuno-Oncology Competitive Landscape Analysis and Market Dynamic; 12.2.1 Immuno-Oncology Competitive Landscape Analysis; 12.2.2 Global Key Manufacturers Headquarter Location and Key Area Sales; 12.2.3 Market Dynamic
13 Key Companies Analysis: 13.1 Bristol-Myers Squibb; 13.1.1 Bristol-Myers Squibb Basic Company Profile (Employees, Areas Service, Competitors and Contact Information); 13.1.2 Bristol-Myers Squibb Immuno-Oncology Product Portfolio; 13.1.3 Bristol-Myers Squibb Immuno-Oncology Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025); 13.2 Merck & Co., Inc.; 13.2.1 Merck & Co., Inc. Basic Company Profile (Employees, Areas Service, Competitors and Contact Information); 13.2.2 Merck & Co., Inc. Immuno-Oncology Product Portfolio; 13.2.3 Merck & Co., Inc. Immuno-Oncology Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025); 13.3 Roche AG; 13.3.1 Roche AG Basic Company Profile (Employees, Areas Service, Competitors and Contact Information); 13.3.2 Roche AG Immuno-Oncology Product Portfolio; 13.3.3 Roche AG Immuno-Oncology Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025); 13.4 AstraZeneca, Plc; 13.4.1 AstraZeneca, Plc Basic Company Profile (Employees, Areas Service, Competitors and Contact Information); 13.4.2 AstraZeneca, Plc Immuno-Oncology Product Portfolio; 13.4.3 AstraZeneca, Plc Immuno-Oncology Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025); 13.5 Sanofi S.A.; 13.5.1 Sanofi S.A. Basic Company Profile (Employees, Areas Service, Competitors and Contact Information); 13.5.2 Sanofi S.A. Immuno-Oncology Product Portfolio; 13.5.3 Sanofi S.A. Immuno-Oncology Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025); 13.6 Dendreon Pharmaceuticals; 13.6.1 Dendreon Pharmaceuticals Basic Company Profile (Employees, Areas Service, Competitors and Contact Information); 13.6.2 Dendreon Pharmaceuticals Immuno-Oncology Product Portfolio; 13.6.3 Dendreon Pharmaceuticals Immuno-Oncology Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025); 13.7 Novartis; 13.7.1 Novartis Basic Company Profile (Employees, Areas Service, Competitors and Contact Information); 13.7.2 Novartis Immuno-Oncology Product Portfolio; 13.7.3 Novartis Immuno-Oncology Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025); 13.8 Gilead Sciences Inc.; 13.8.1 Gilead Sciences Inc. Basic Company Profile (Employees, Areas Service, Competitors and Contact Information); 13.8.2 Gilead Sciences Inc. Immuno-Oncology Product Portfolio; 13.8.3 Gilead Sciences Inc. Immuno-Oncology Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025); 13.9 Merck KGaA; 13.9.1 Merck KGaA Basic Company Profile (Employees, Areas Service, Competitors and Contact Information); 13.9.2 Merck KGaA Immuno-Oncology Product Portfolio; 13.9.3 Merck KGaA Immuno-Oncology Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
14 Industry Chain Analysis: 14.1 Immuno-Oncology Industry Chain Analysis; 14.2 Immuno-Oncology Industry Raw Material and Suppliers Analysis; 14.2.1 Immuno-Oncology Key Raw Material Supply Analysis; 14.2.2 Raw Material Suppliers and Contact Information; 14.3 Immuno-Oncology Typical Downstream Customers; 14.4 Immuno-Oncology Sales Channel Analysis
15 Research Findings and Conclusion
16 Methodology and Data Source: 16.1 Methodology/Research Approach; 16.2 Research Scope; 16.3 Benchmarks and Assumptions; 16.4 Date Source; 16.4.1 Primary Sources; 16.4.2 Secondary Sources; 16.5 Data Cross Validation; 16.6 Disclaimer